Stay updated on Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial
Sign up to get notified when there's something new on the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page.

Latest updates to the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedRevision: v3.3.3 was added to the record history, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' entries were removed from the footer/versions view; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRecord History now shows Revision: v3.3.2 in place of Revision: v3.3.1. This is a minor UI label change and does not affect study data or functionality.SummaryDifference0.1%

- Check49 days agoChange DetectedThe record history now includes an added Revision v3.3.1 entry and the v3.2.0 entry has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedThe notice about government funding and operating status at the top of the page was removed, with no impact on study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check71 days agoChange DetectedNo new content was added or removed; the page only displays the existing Record History with version dates.SummaryDifference0.1%

- Check99 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference13%

Stay in the know with updates to Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page.